| Title: |
Bradykinin Contributes to the Systemic Hemodynamic Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure |
| Authors: |
Cruden, Nicholas L.M.; Witherow, Fraser N.; Webb, David J.; Fox, Keith A.A.; Newby, David E. |
| Source: |
Arteriosclerosis, Thrombosis, and Vascular Biology ; volume 24, issue 6, page 1043-1048 ; ISSN 1079-5642 1524-4636 |
| Publisher Information: |
Ovid Technologies (Wolters Kluwer Health) |
| Publication Year: |
2004 |
| Description: |
Background— Bradykinin is an endogenous vasodilator that may contribute to the systemic effects of angiotensin-converting enzyme (ACE) inhibitor therapy. Using B9340, a bradykinin receptor antagonist, we determined the contribution of bradykinin to the systemic hemodynamic effects of long-term ACE inhibition in patients with chronic heart failure. Methods and Results— Fourteen patients with heart failure received enalapril (10 mg twice daily) or losartan (50 mg twice daily) in a randomized double-blind crossover trial. After 6 weeks treatment, patients underwent right heart catheterization and were randomized to an intravenous infusion of B9340 (2 to 20 μg/kg per minute) or saline placebo. After B9340 infusion in patients treated with enalapril, mean arterial pressure (+5.2 mm Hg), systemic vascular resistance (+315 dynes·s/cm 5 ), pulmonary arterial wedge pressure (−1.4 mm Hg), and mean pulmonary arterial pressure (−1.3 mm Hg) were greater compared with losartan ( P |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1161/01.atv.0000129331.21092.1d |
| DOI: |
10.1161/01.ATV.0000129331.21092.1d |
| Availability: |
https://doi.org/10.1161/01.atv.0000129331.21092.1d; https://www.ahajournals.org/doi/full/10.1161/01.ATV.0000129331.21092.1d |
| Accession Number: |
edsbas.7EF5A77A |
| Database: |
BASE |